Enstasis Therapeutics starts business in anti bacterials with ETX 0914

Entasis Therapeutics, a company leveraging its expertise and a unique pathogen-targeted approach to develop and advance novel antibacterials and spin off from AstraZeneca, debuted with a portfolio of diverse, innovative investigational drugs for the treatment of serious drug-resistant bacterial infections. Entasis� robust pipeline consists of clinical and preclinical programs, including ETX 0914, which is a first-in-class, novel oral antibiotic currently in Phase II for the treatment of uncomplicated gonorrhea. ETX 0914 has been designated a Qualified Infectious Disease Product (QIDP) by the FDA and awarded Fast-Track status. Other preclinical programs target serious Gram-negative infections often associated with acute care settings, including Pseudomonas aeruginosa, Acinetobacter baumannii and carbapenem-resistant Enterobacteriaceae. Entasis� drug discovery platform combines the use of genetic tools, molecular dynamics simulations, and modeling, to enable exploration of novel therapies in a more directed, focused way to design compounds with improved efficacy for these very challenging pathogens.